E-ISSN 2231-3206 | ISSN 2320-4672
 
2023, Vol: 13, Issue: 3
13/3Current Issue Online FirstArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles
Required files to be uploaded

Authorship Declaration

Original Research 


High-sensitive C-reactive protein levels in diabetes associated with dyslipidemia

Yousef Rezaei Chianeh, Krishnananda Prabhu, Vinutha R. Bhat, Padmanabha Udupa, Azadeh Bagheri, Shivananda Baliga, Ravi Teja Chelikani.

Abstract
Background: There is compelling evidence that inflammation is an important risk factor in cardiovascular disease (CVD) and diabetes mellitus. High-sensitive C-reactive protein (hs-CRP) is a predictive marker of inflammation as well as metabolic syndrome.

Aims and Objectives: The purpose of this study was to correlate the significance of hs-CRP with cholesterol, triglyceride (TG), high density lipoprotein cholesterol (HDL-C), and low density lipoprotein (LDL) in patients with long-term hyperglycemia and healthy control group.

Materials and Methods: This study involved 311 subjects (150 patients, 161 control group; between 40 and 65 years of age, mean age of patients and control group were 51.4 ± 9.6, 45.96 ± 3, respectively). Serum concentration of aforementioned analytes was measured among the patients and controls.

Results: The concentration of parameters among case and control group were total cholesterol (227.84 ± 28.3, 167.45 ± 21.63 mg/dl), LDL cholesterol (158.43 ± 25.65, 117.30 ± 31.27 mg/dl), HDL-C (27.67 ± 11.11, 51.74 ± 12.61 mg/dl), TG (211.34 ± 36.42, 98.13 ± 67.40 mg/dl), and hs-CRP (29.49 ± 5.90, 2.18 ± 1.10 mg/L) were measured by Cobas 6000 autoanalyzer. A statistically significant (P < 0.001) difference was found in both groups.

Conclusion: Diabetes mellitus has a profound effect on lipid metabolism and patient’s lipid profile need to be monitored and managed frequently to prevent further complication such as CVD that may arise as a result of dyslipidemia.

Key words: High Density Lipoprotein Cholesterol; Total Cholesterol; Low Density Lipoprotein Cholesterol; High-sensitive C-reactive Protein


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Yousef Rezaei Chianeh
Articles by Krishnananda Prabhu
Articles by Vinutha R. Bhat
Articles by Padmanabha Udupa
Articles by Azadeh Bagheri
Articles by Shivananda Baliga
Articles by Ravi Teja Chelikani
on Google
on Google Scholar


REFERENCES
1. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98(8):731-3. [DOI via Crossref]    [Pubmed]   
2. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998;97(5):425-8. [DOI via Crossref]    [Pubmed]   
3. Chianeh YR, Ahuja J, Prasad A. Evaluation of oxidative protein damage in patients with hypercholesterolemia. Natl J Integr Res Med. 2013;4(4):64-8.
4. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med. 1999;340(2):115-26. [DOI via Crossref]    [Pubmed]   
5. Ridker PM. Evaluating novel cardiovascular risk factors: Can we better predict heart attacks? Ann Intern Med. 1999;130(11):933-7. [DOI via Crossref]    [Pubmed]   
6. Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, et al. C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon? Circulation. 1999;100(1):96-102. [DOI via Crossref]    [Pubmed]   
7. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836-43. [DOI via Crossref]    [Pubmed]   
8. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple risk factor intervention trial. Am J Epidemiol. 1996;144(6):537-47.
9. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336(14):973-9. [DOI via Crossref]    [Pubmed]   
10. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the cardiovascular health study and the rural health promotion project. Arterioscler Thromb Vasc Biol. 1997;17(6):1121-7. [DOI via Crossref]    [Pubmed]   
11. Roivainen M, Viik-Kajander M, Palosuo T, Toivanen P, Leinonen M, Saikku P, et al. Infections, inflammation, and the risk of coronary heart disease. Circulation. 2000;101(3):252-7. [DOI via Crossref]    [Pubmed]   
12. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106(5):506-12. [DOI via Crossref]   
13. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses. BMJ. 2000;321(7255):199-204. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
14. Mendall MA, Strachan DP, Butland BK, Ballam L, Morris J, Sweetnam PM, et al. C-reactive protein: Relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J. 2000;21(19):1584-90. [DOI via Crossref]    [Pubmed]   
15. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994;331(7):417-24. [DOI via Crossref]    [Pubmed]   
16. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: A TIMI 11A substudy. Thrombolysis in myocardial infarction. J Am Coll Cardiol. 1998;31(7):1460-5. [DOI via Crossref]   
17. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation. 1999;99(7):855-60. [DOI via Crossref]    [Pubmed]   
18. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC study group. Fragmin during instability in coronary artery disease. Circulation. 1997;96(12):4204-10. [DOI via Crossref]    [Pubmed]   
19. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European concerted action on thrombosis and disabilities angina pectoris study group. Lancet. 1997;349(9050):462-6. [DOI via Crossref]   
20. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events (CARE) investigators. Circulation. 1998;98(9):839-44. [DOI via Crossref]    [Pubmed]   
21. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing Type 2 diabetes mellitus. JAMA. 2001;286(3):327-34. [DOI via Crossref]    [Pubmed]   
22. Khera A, McGuire DK, Murphy SA, Stanek HG, Das SR, Vongpatanasin W, et al. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol. 2005;46(3):464-9. [DOI via Crossref]    [Pubmed]   
23. Chambers JC, Eda S, Bassett P, Karim Y, Thompson SG, Gallimore JR, et al. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation. 2001;104(2):145-50. [DOI via Crossref]    [Pubmed]   
24. Forouhi NG, Sattar N, McKeigue PM. Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Int J Obes Relat Metab Disord. 2001;25(9):1327-31. [DOI via Crossref]    [Pubmed]   
25. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: HA statement for healthcare professionals from the centers for disease control and prevention and the American heart association. Circulation. 2003;107(3):499-511. [DOI via Crossref]    [Pubmed]   

How to Cite this Article
Pubmed Style

Yousef Rezaei Chianeh, Krishnananda Prabhu, Vinutha R. Bhat, Padmanabha Udupa, Azadeh Bagheri, Shivananda Baliga, Ravi Teja Chelikani. High-sensitive C-reactive protein levels in diabetes associated with dyslipidemia. Natl J Physiol Pharm Pharmacol. 2016; 6(5): 480-483. doi:10.5455/njppp.2016.6.0615715072016

Web Style

Yousef Rezaei Chianeh, Krishnananda Prabhu, Vinutha R. Bhat, Padmanabha Udupa, Azadeh Bagheri, Shivananda Baliga, Ravi Teja Chelikani. High-sensitive C-reactive protein levels in diabetes associated with dyslipidemia. https://www.njppp.com/?mno=232206 [Access: March 01, 2023]. doi:10.5455/njppp.2016.6.0615715072016

AMA (American Medical Association) Style

Yousef Rezaei Chianeh, Krishnananda Prabhu, Vinutha R. Bhat, Padmanabha Udupa, Azadeh Bagheri, Shivananda Baliga, Ravi Teja Chelikani. High-sensitive C-reactive protein levels in diabetes associated with dyslipidemia. Natl J Physiol Pharm Pharmacol. 2016; 6(5): 480-483. doi:10.5455/njppp.2016.6.0615715072016


Vancouver/ICMJE Style

Yousef Rezaei Chianeh, Krishnananda Prabhu, Vinutha R. Bhat, Padmanabha Udupa, Azadeh Bagheri, Shivananda Baliga, Ravi Teja Chelikani. High-sensitive C-reactive protein levels in diabetes associated with dyslipidemia. Natl J Physiol Pharm Pharmacol. (2016), [cited March 01, 2023]; 6(5): 480-483. doi:10.5455/njppp.2016.6.0615715072016


Harvard Style

Yousef Rezaei Chianeh, Krishnananda Prabhu, Vinutha R. Bhat, Padmanabha Udupa, Azadeh Bagheri, Shivananda Baliga, Ravi Teja Chelikani (2016) High-sensitive C-reactive protein levels in diabetes associated with dyslipidemia. Natl J Physiol Pharm Pharmacol, 6 (5), 480-483. doi:10.5455/njppp.2016.6.0615715072016


Turabian Style

Yousef Rezaei Chianeh, Krishnananda Prabhu, Vinutha R. Bhat, Padmanabha Udupa, Azadeh Bagheri, Shivananda Baliga, Ravi Teja Chelikani. 2016. High-sensitive C-reactive protein levels in diabetes associated with dyslipidemia. National Journal of Physiology, Pharmacy and Pharmacology, 6 (5), 480-483. doi:10.5455/njppp.2016.6.0615715072016


Chicago Style

Yousef Rezaei Chianeh, Krishnananda Prabhu, Vinutha R. Bhat, Padmanabha Udupa, Azadeh Bagheri, Shivananda Baliga, Ravi Teja Chelikani. "High-sensitive C-reactive protein levels in diabetes associated with dyslipidemia." National Journal of Physiology, Pharmacy and Pharmacology 6 (2016), 480-483. doi:10.5455/njppp.2016.6.0615715072016


MLA (The Modern Language Association) Style

Yousef Rezaei Chianeh, Krishnananda Prabhu, Vinutha R. Bhat, Padmanabha Udupa, Azadeh Bagheri, Shivananda Baliga, Ravi Teja Chelikani. "High-sensitive C-reactive protein levels in diabetes associated with dyslipidemia." National Journal of Physiology, Pharmacy and Pharmacology 6.5 (2016), 480-483. Print. doi:10.5455/njppp.2016.6.0615715072016


APA (American Psychological Association) Style

Yousef Rezaei Chianeh, Krishnananda Prabhu, Vinutha R. Bhat, Padmanabha Udupa, Azadeh Bagheri, Shivananda Baliga, Ravi Teja Chelikani (2016) High-sensitive C-reactive protein levels in diabetes associated with dyslipidemia. National Journal of Physiology, Pharmacy and Pharmacology, 6 (5), 480-483. doi:10.5455/njppp.2016.6.0615715072016


Author LoginReviewer LoginAbout PublisherEditorial PoliciesPeer Review PolicyEditorial & Peer Review ProcessPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesStatement of Informed ConsentAdvertising PolicyTerms of UseLicense InformationCopyright Information
Copyright © 2023 National Journal of Physiology, Pharmacy and Pharmacology All Rights Reserved. Subject to change without notice from or liability to National Journal of Physiology, Pharmacy and Pharmacology.
For best results, please use Internet Explorer or Google Chrome

Contact Information


Publisher

publishernjppp@gmail.com

 

Editorial query

editornjppp1@gmail.com

MOB - 8780040272